Download presentation
Presentation is loading. Please wait.
Published byἈμβρόσιος Αλεξάκης Modified over 6 years ago
1
Long-Term Disease Control by Pomalidomide-/Dexamethasone-Based Therapy in a Patient with Advanced Multiple Myeloma: A Case Report and Review of the Literature Case Rep Oncol 2015;8: DOI: / Fig. 1. Cytomorphology of a bone marrow aspirate smear (×63) performed in August 2010 showing high-grade diffuse infiltration with atypical plasma cells. © 2015 S. Karger AG, Basel - CC BY-NC 3.0
2
Long-Term Disease Control by Pomalidomide-/Dexamethasone-Based Therapy in a Patient with Advanced Multiple Myeloma: A Case Report and Review of the Literature Case Rep Oncol 2015;8: DOI: / Fig. 2. Disease course based on M protein levels indicated in months after primary diagnosis (DX).Benda = Bendamustine; Len = lenalidomide; Dex = dexamethasone; Bort = bortezomib; Cyclo = cyclophosphamide; Mel = melphalan; Poma = pomalidomide; VCD = bortezomib/cyclophosphamide/dexamethasone. © 2015 S. Karger AG, Basel - CC BY-NC 3.0
3
Long-Term Disease Control by Pomalidomide-/Dexamethasone-Based Therapy in a Patient with Advanced Multiple Myeloma: A Case Report and Review of the Literature Case Rep Oncol 2015;8: DOI: / Fig. 3. Radiograph of a pathological humeral fracture corresponding to serological disease progression in June Imaging after osteosynthesis with a proximally and distally fixed intramedullary nail. © 2015 S. Karger AG, Basel - CC BY-NC 3.0
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.